Know Cancer

or
forgot password

Phase I/II Study Evaluating the Safety and Efficacy of Leuvectin Immunotherapy for the Treatment of Locally Recurrent Prostate Cancer Following Radiation Therapy (Summary Last Updated: 02/2001)


Phase 1/Phase 2
18 Years
N/A
Open (Enrolling)
Male
Prostate Cancer

Thank you

Trial Information

Phase I/II Study Evaluating the Safety and Efficacy of Leuvectin Immunotherapy for the Treatment of Locally Recurrent Prostate Cancer Following Radiation Therapy (Summary Last Updated: 02/2001)


OBJECTIVES: I. Determine the toxicity and tolerability of leuvectin in patients with locally
recurrent organ-confined prostate cancer after radiotherapy. II. Determine the efficacy of
this regimen in preventing or delaying manifestations of disease progression as demonstrated
by biochemical failure or clinical recurrence in this patient population.

OUTLINE: This is an open-label, multicenter study. Patients receive leuvectin
intraprostatically over 10-30 seconds under transrectal ultrasound guidance on days 0 and
14. Patients are re-evaluated at week 10. Treatment repeats every 10-11 weeks or 1-6 days
after completion of each week 10 re-evaluation for a maximum of 3 courses in the absence of
disease progression or unacceptable toxicity. Patients are followed every 3 months for 1
year and then every 6 months for 2 years in the absence of disease progression.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS: Histologically proven locally recurrent organ-confined prostate
cancer after external beam radiotherapy, radiation seed implants, or cryosurgery Gleason
score at least 6 PSA at least 1.0 ng/mL with 2 consecutive rises in PSA at least 2 weeks
apart, of which the second increase is greater than the first, after achieving a nadir
Must have at least 3 recorded PSA values over a minimum of the last 3 months to determine
the slope Patients must have declined additional conventional treatment or be ineligible
for conventional treatment of their prostate cancer No metastasis by bone scan No
significant CNS disease

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 80-100% OR ECOG 0
or 1 Life expectancy: Not specified Hematopoietic: WBC greater than 3,000/mm3 Platelet
count greater than 100,000/mm3 Hemoglobin greater than 9.0 g/dL Hepatic: Bilirubin normal
SGOT or SGPT less than 3 times upper limit of normal Albumin greater than 3 g/dL PT and
PTT normal Hepatitis B surface antigen negative Renal: Creatinine normal Cardiovascular:
No uncontrolled hypertension No significant cardiovascular disease, e.g.: History of
ventricular dysfunction Congestive heart failure Symptoms of coronary artery disease
History of any ventricular arrhythmia Prior myocardial infarction Other: HIV negative
Fertile patients must use effective double-barrier contraception during and for 3 months
after study participation No active autoimmune disease No active infection requiring IV
antibiotics No uncontrolled diabetes mellitus No significant psychiatric disorder that
would preclude study No other malignancy within the past 5 years except adequately treated
basal cell or squamous cell skin cancer

PRIOR CONCURRENT THERAPY: Biologic therapy: No prior leuvectin Chemotherapy: At least 3
weeks since prior chemotherapy (6 weeks for mitomycin or hydroxyurea) Endocrine therapy:
No prior hormonal therapy for prostate cancer Radiotherapy: See Disease Characteristics At
least 3 weeks since prior radiotherapy Surgery: At least 1 month since prior intrathoracic
or intra-abdominal surgery At least 2 weeks since other prior major surgery Other: At
least 10 days since prior anticoagulants or non-steroidal anti-inflammatory agents No
neoadjuvant or other concurrent anticancer drug therapy No concurrent immunosuppressive
drugs No other concurrent experimental therapy

Type of Study:

Interventional

Study Design:

Primary Purpose: Treatment

Principal Investigator

Arie Belldegrun, MD, FACS

Investigator Role:

Study Chair

Investigator Affiliation:

Jonsson Comprehensive Cancer Center

Authority:

United States: Federal Government

Study ID:

CDR0000067677

NCT ID:

NCT00005072

Start Date:

November 2000

Completion Date:

Related Keywords:

  • Prostate Cancer
  • stage I prostate cancer
  • stage IIB prostate cancer
  • stage IIA prostate cancer
  • recurrent prostate cancer
  • Prostatic Neoplasms

Name

Location

Jonsson Comprehensive Cancer Center, UCLALos Angeles, California  90095-1781
Cleveland Clinic Taussig Cancer CenterCleveland, Ohio  44195